Lena Tholen, Ph.D, Director of Cell Line and Bioprocess Development at FyoniBio and Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech weigh in early on important cell line selection considerations for novel protein therapeutics in this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics.
Check out the full webinar available on-demand - [ Ссылка ]
